Osong Medical Innovation Foundation, Korea University Research and Business Foundation

Wellmarker Bio Co., Ltd.

Stemmedience Co., Ltd.

Jai-Hee Moon

Jung Han Lee

Byung Sun Yoon

Seungkwon You

Eun Kyoung Jun

Jun Sung Kim

June Seok Heo

Hyunho Lee

Ji Hyun Kim

Jong Won Lee

HyoJin Kim

Jang Ho Lee

Chun-Ho Park

Hyebin Park

Joseph Kim

Yoon-Sun Park

Seung-Woo Hong

Ji Hye Hwang

Su Hyun Gwon

Sun Chul Hur

Jae-Sik Shin

Sohee Lee

Jonggun Kim

Kyoung Shik Cho

Hye-Youn Jung

Hwang Heui Lee

Eulsoon Park

Isaac Maeng

A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions containing the thienopyridine compound can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.

Thienopyridine derivatives and pharmaceutical composition comprising same

Disclosed is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule coding for Bmi1; and b) an Oct4 protein or a nucleic acid molecule coding for Oct4. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the genetic factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.

Composition for reprogramming somatic cells to generate induced pluripotent stem cells, comprising Oct4 in combination with Bmi1 or its upstream regulator, and method for generating induced pluripotent stem cells using the same

The present invention relates to a culture medium for the fetus-derived mesenchymal stem cells in amniotic fluid. More particularly, the present invention relates to a composition for improving skin conditions, comprising the culture medium of fetus-derived mesenchymal stem cells in amniotic fluid as an active ingredient, in which the skin conditions to be improved include whitening, wrinkles, skin damages caused by UV rays or skin lifting. Further, the present invention relates to a method for preparing the composition, comprising the steps of culturing the fetus-derived mesenchymal stem cells in amniotic fluid; and collecting the culture medium.

Composition for improving skin conditions using fetal mesenchymal stem cells from amniotic fluid

Provided is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule encoding the Bmi1 protein; and b) at least one low molecular weight substance selected from the group consisting of a set of a MEK/ERK (mitogen-activated protein kinase/extracellular regulated kinase) inhibitor and a GSK (glycogen synthase kinase) inhibitor, a set of a G9a HMTase (G9a histone methyltransferase) inhibitor and a DMNT (DNA methyltransferase) inhibitor, and a histone deacetylase inhibitor. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the reprogramming factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.

Composition for reprogramming somatic cells to generate induced pluripotent stem cells, comprising Bmi1 and low molecular weight substance, and method for generating induced pluripotent stem cells using the same

Growing community of inventors

Seoul, South Korea

Jai-Hee Moon